ALBANY, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)REGENERATIVE RESEARCH FOUNDATION, founded in 2005, is a community nonprofit in the Medical Research sector that reported $7.0M in total revenue in fiscal year 2024. Revenue fell 20% from the prior year — a significant decline worth monitoring. Expenses of $6.5M left a modest 7% surplus.
THE PRINCIPAL MISSION OF THE REGENERATIVE RESEARCH FOUNDATION IS TO DEVELOP REGENERATIVE STEM CELL THERAPIES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS): THE BRAIN, SPINAL CORD, AND RETINA.
FISCAL YEAR 2024 WAS AN EVENTFUL AND PRODUCTIVE YEAR FOR THE REGENERATIVE RESEARCH FOUNDATION. ON OCTOBER 1, 2024 THE FOUNDATION MOVED TO A NEW LABORATORY FACILITY LOCATED IN ALBANY, NY. THE...
FISCAL YEAR 2024 WAS AN EVENTFUL AND PRODUCTIVE YEAR FOR THE REGENERATIVE RESEARCH FOUNDATION. ON OCTOBER 1, 2024 THE FOUNDATION MOVED TO A NEW LABORATORY FACILITY LOCATED IN ALBANY, NY. THE RELOCATION WAS ACCOMPLISHED WITHOUT INCIDENT AND RESEARCH ACTIVITIES RESUMED QUICKLY TO NORMAL LEVELS. FOUNDATION RESEARCHERS PUBLISHED SEVERAL ARTICLES IN PROMINENT SCIENTIFIC JOURNALS REPORTING THE RESULTS OF THEIR INVESTIGATIONS INTO NEURODEGENERATIVE DISEASES SUCH AS DEMENTIA AND POTENTIAL TREATMENTS FOR DISEASES OF THE NERVOUS SYSTEM. THESE PUBLICATIONS WERE MADE FREELY AVAILABLE TO THE RESEARCH COMMUNITY AND GENERAL PUBLIC THROUGH THE NATIONAL LIBRARY OF MEDICINE OPEN ACCESS REPOSITORY. THE FOUNDATION RESEARCHERS WERE ABLE TO SECURE 8 NEW GRANTS WHICH PROVIDE FINANCIAL SUPPORT FOR THEIR RESEARCH ACTIVITIES.
THE PHASE 1/2A CLINICAL TRIAL COMPLETED ITS FIRST COHORT OF PATIENTS DURING CALENDAR YEAR 2024. THE STUDY CONTINUES TO RECRUIT SUBJECTS AND AT IN DISCUSSIONS WITH A POTENTIAL SECOND CLINICAL SITE...
THE PHASE 1/2A CLINICAL TRIAL COMPLETED ITS FIRST COHORT OF PATIENTS DURING CALENDAR YEAR 2024. THE STUDY CONTINUES TO RECRUIT SUBJECTS AND AT IN DISCUSSIONS WITH A POTENTIAL SECOND CLINICAL SITE WHICH WILL EXPAND THE SUBJECT RECRUITMENT POPULATION. THE PRINCIPAL INVESTIGATOR, DR. JEFFREY STERN, PRESENTED STUDY RESULTS AS AN INVITED SPEAKER AT THE NATIONAL EYE INSTITUTE. THE INSTITUTE WAS ALSO SUCCESSFUL IN OBTAINING REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FROM THE FDA FOR ITS CELL-BASED THERAPY.
THE ALZHEIMER'S DISEASE AND RELATED DEMENTIAS RESEARCH PROGRAM CONTINUED ITS MISSION TO EXPAND THE UNDERSTANDING AND DEVELOPMENT OF A POTENTIAL TREATMENT FOR THESE NEURODEGENERATIVE DISEASES. THE...
THE ALZHEIMER'S DISEASE AND RELATED DEMENTIAS RESEARCH PROGRAM CONTINUED ITS MISSION TO EXPAND THE UNDERSTANDING AND DEVELOPMENT OF A POTENTIAL TREATMENT FOR THESE NEURODEGENERATIVE DISEASES. THE INSTITUTE SERVES AS THE LEAD ORGANIZATION FOR A CONSORTIUM OF INSTITUTIONS AND INVESTIGATORS FOCUSED ON IDENTIFYING GENES ASSOCIATED WITH THE DEVELOPMENT OF DEMENTIA. THE NATIONAL INSTITUTES OF HEALTH AND SEVERAL PUBLIC CHARITIES SUPPORT THIS UNDERTAKING BOTH PROGRAMMATICALLY AND FINANCIALLY. THE FOUNDATION IS SEEKING BIOTECH PARTNERSHIPS TO SUPPORT RESEARCH AND DEVELOPMENT OF A PROMISING NEURODEGENERATIVE DISEASE TREATMENT.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $7,006,538 | $8,795,245 | -0.2% |
| Expenses | $6,491,048 | $7,305,106 | -0.1% |
| Net Income | $515,490 | $1,490,139 | -0.7% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| WILLIAM KAHN CPA | CHAIR | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| JEFFREY H STERN MD PHD | DIRECTOR FOR TRANSLATIONAL | 30.00 |
Officer
Director
|
$53,025 | $510 | $53,535 |
| JOHN WALSH | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| VITO GRASSO MPA CAE | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| DAVID O CARPENTER MD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| DAWN ABBUHL | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| ROBERT CATALANO MD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| AMY G KLANN PHD JD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| SALLY TEMPLE-STERN PHD | SCIENTIFIC & EXECUTIVE DIR | 65.00 |
Officer
|
$173,942 | $21,897 | $195,839 |
| CAITLIN HILL | PRINCIPAL INVESTIGATOR | 40.00 |
Highest
|
$135,055 | $6,756 | $141,811 |
| THOMAS KIEHL | PRINCIPAL INVESTIGATOR | 40.00 |
Highest
|
$131,200 | $14,982 | $146,182 |
| GLENNA FORD | CLINICAL TRIAL MANAGER | 40.00 |
Highest
|
$139,694 | $15,319 | $155,013 |
| DAVID BUTLER PHD | PRINCIPAL INVESTIGATOR | 60.00 |
Highest
|
$101,541 | $5,314 | $106,855 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $7,006,538 | $6,491,048 | $9,028,494 | $515,490 |
| 2023 | $8,795,245 | $7,305,106 | $6,996,425 | $1,490,139 |
| 2022 | $7,532,149 | $5,849,247 | $5,981,949 | $1,682,902 |
| 2021 | $5,099,449 | $4,611,189 | $4,518,761 | $488,260 |
| 2020 | $3,574,825 | $3,718,838 | $2,551,269 | $-144,013 |
| 2019 | $3,531,037 | $3,699,830 | $2,293,624 | $-168,793 |
| 2018 | $3,248,836 | $3,843,206 | $2,574,291 | $-594,370 |
Compare REGENERATIVE RESEARCH FOUNDATION with other nonprofits in New York and across the country.